Moreover, in patients suffering from TNBC with the positive expression of programmed death 1 (PD-1) in cancer cells or programmed death ligand 1 (PD-L1) occurring in tumor-infiltrating immune cells, the inhibition of PD1/PD-L1 may be a hopeful treatment strategy9,10. This evidence concerns the gene CD274 and cancer.